XML 34 R24.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Summary of net loss reconciliation

The following table shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under U.S. GAAP, to the Company’s total net loss in the statements of operations and comprehensive loss, for the three and nine months ended September 30, 2025, and 2024 (in thousands):

Three Months Ended September 30,

Nine Months Ended September 30,

    

2025

    

2024

2025

    

2024

Denifanstat external research and
development expenses

5,784

11,888

 

23,878

 

21,167

TVB-3567 external research and development
expenses

2,735

208

 

4,955

 

223

External general and administrative expenses

 

2,315

 

1,971

6,946

6,313

Personnel costs

1,733

1,707

5,459

4,701

Stock-based compensation

1,688

1,546

 

4,758

 

3,754

Other segment items (1)

 

(1,347)

 

(2,701)

(4,526)

(6,792)

Segment net loss

$

12,908

$

14,619

$

41,470

$

29,366

(1)Other segment items consist of (i) interest and other income, net and (ii) other internal operating research and development expenses.